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Abstract
Survival of dystrophin/utrophin double-knockout (dko) mice was increased by muscle-specific expression of a neuronal
nitric oxide synthase (nNOS) transgene. Dko mice expressing the transgene (nNOS TG+/dko) experienced delayed onset of
mortality and increased life-span. The nNOS TG+/dko mice demonstrated a significant decrease in the concentration of
CD163+, M2c macrophages that can express arginase and promote fibrosis. The decrease in M2c macrophages was
associated with a significant reduction in fibrosis of heart, diaphragm and hindlimb muscles of nNOS TG+/dko mice. The
nNOS transgene had no effect on the concentration of cytolytic, CD68+, M1 macrophages. Accordingly, we did not observe
any change in the extent of muscle fiber lysis in the nNOS TG+/dko mice. These findings show that nNOS/NO (nitric oxide)-
mediated decreases in M2c macrophages lead to a reduction in the muscle fibrosis that is associated with increased
mortality in mice lacking dystrophin and utrophin. Interestingly, the dramatic and beneficial effects of the nNOS transgene
were not attributable to localization of nNOS protein at the cell membrane. We did not detect any nNOS protein at the
sarcolemma in nNOS TG+/dko muscles. This important observation shows that sarcolemmal localization is not necessary for
nNOS to have beneficial effects in dystrophic tissue and the presence of nNOS in the cytosol of dystrophic muscle fibers can
ameliorate the pathology and most importantly, significantly increase life-span.
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Introduction
Duchenne muscular dystrophy (DMD) is an inherited, fatal
disease of muscle wasting that affects 1 in 3500 newborn males [1].
DMD patients experience progressive muscle atrophy, which
results in loss of function, respiratory insufficiencies and cardiac
abnormalities [1,2]. Most patients lose the ability to ambulate by
age 12 [2], begin using ventilatory assistance in the late teens [3],
and all patients suffer from clinical cardiac involvement by age 18
[4]. There is no cure or well-tolerated treatment for DMD and
death typically occurs in the late teens or early twenties due to
respiratory or cardiac complications [2,4]. The genetic basis for
DMD is a mutation of the dystrophin gene that prevents
expression of dystrophin protein [5]. Dystrophin is normally
localized beneath the sarcolemma where it anchors a membrane-
spanning protein complex, the dystrophin glycoprotein complex
(DGC), which links the cytoskeleton to the extracellular matrix
and provides membrane stabilization [6]. Absence of dystrophin
results in loss of the DGC proteins and destabilization of the
sarcolemma making the muscle cell membrane more susceptible to
mechanical damage and subsequent necrosis [7,8]. The muscle
pathology is exacerbated by phenotypically-distinct populations of
inflammatory cells that lyse muscle cells and promote pathological
fibrosis. The greatest proportion of invading immune cells are
classically-activated, M1 macrophages that lyse muscle cells via
inducible nitric oxide synthase (iNOS)-mediated mechanisms [9].
Also present in dystrophic muscle are arginase-expressing, M2
macrophages that are associated with repair processes and
promote connective tissue deposition to drive the pathological
fibrosis that is characteristic of the disease [9,10]. Ultimately,
deficiencies in the regenerative capacity of dystrophin-deficient
muscle preclude normal repair of the tissue and the necrotic fibers
are eventually replaced with connective tissue that permanently
compromises function [11].
Secondary effects of the dystrophin mutation, such as loss of
DGC proteins, complicate the dystrophic pathophysiology.
Neuronal nitric oxide synthase (nNOS) is normally localized to
the sarcolemma via associations with other DGC proteins [12].
However, in dystrophin-deficient muscle, nNOS is absent from the
sarcolemma and greatly downregulated in the cytoplasm [12,13].
The loss of muscle nNOS has significant physiological effects
because its metabolic product, nitric oxide (NO), is a signaling
molecule with diverse, systemic functions. Most relevant to the
dystrophic muscle pathology, NO is a potent anti-inflammatory
molecule that can inhibit the infiltration and activation of
inflammatory cells [14,15] as well as scavenge cytolytic molecules
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that the loss of nNOS in dystrophic muscle results in significant
inflammation, inflammatory cell-mediated damage and fibrosis
[17,18].
Normalizing NO production by expressing a nNOS transgene
in dystrophin-deficient mdx mouse muscle and cardiac tissue
significantly ameliorates the dystrophic pathology. The mdx mouse
is a naturally-occurring model of DMD that carries a premature
stop codon in the dystrophin gene [19] and displays similar disease
characteristics to DMD patients including progressive weakness,
fiber damage, inflammation, fibrosis and cardiac pathology
[17,20–22]. Expression of a nNOS transgene in mdx skeletal
muscle decreased infiltration of cytotoxic macrophages and
reduced subsequent lysis of muscle fibers thereby significantly
attenuating the histopathology [17]. Myocardial expression of a
nNOS transgene completely prevented cardiac fibrosis in aged mdx
mice and normalized or improved aspects of the cardiac pathology
that are often fatal [18]. These benefits of nNOS transgene
expression likely resulted from reductions in profibrotic, inflam-
matory cells and restoration of competition between nNOS and
arginase for their common substrate, arginine [9,10]. The lack of
nNOS activity in dystrophic muscle creates increased arginine
availability for metabolism by arginase-expressing, M2 macro-
phages as well as a loss of metabolites normally generated from
oxidation of arginine by nNOS that inhibit arginase activity [9,23–
26]. Metabolism of arginine by arginase activates pro-fibrotic
pathways and promotes connective tissue deposition in muscle
[10,27–30]. When the nNOS transgene is expressed in dystrophic
muscle, arginine can be diverted from the pro-fibrotic, arginase
pathway and metabolized by nNOS to generate NO for protective
functions [10]. These observations show that increasing nNOS
expression and activity can ameliorate components of the
dystrophin-deficient pathology that contribute to mortality
suggesting that the nNOS transgene could affect life-span.
Though the mdx dystrophy is genetically homologous to DMD
and shares many characteristics of the human disease, DMD and
mdx pathologies differ distinctly. For example, the DMD is
characterized by progressive muscle wasting that results in
premature death. However, the mdx mouse undergoes significant
regeneration following an early phase of necrosis and lives a nearly
normal life-span [21,31] making it impractical for analyses in
which survival is an outcome measure. The mild, mdx phenotype is
attributed to endogenous upregulation of the dystrophin homo-
logue, utrophin, at the sarcolemma where it can functionally
compensate for the loss of dystrophin [32–33]. Mice that lack
expression of both dystrophin and utrophin (double knockout
(dko)) experience a very severe disease course that phenotypically
resembles the DMD dystrophy despite the genetic heterogeneity of
the two pathologies. Dko mice experience an early disease onset
characterized by severe and progressive atrophy, weight loss after
weaning, contractures, kyphosis, respiratory difficulty, cardiac
involvement and early death by 14 weeks of age [20,34,35].
In this investigation, we tested whether increasing nNOS
expression improves survival of dko mice. Our previous studies
using dystrophin-deficient mice showed that reductions of nNOS
and NO in dystrophic muscle and heart significantly contribute to
multiple elements of the pathology including inflammatory cell-
mediated muscle fiber damage, fibrosis and cardiac dysfunction
[10,17,18]. We hypothesize that NO-mediated amelioration of
these components of the pathology will extend the life-span of dko
mice. We tested our hypothesis by generating nNOS transgene-
expressing mice that were deficient in dystrophin and utrophin
(nNOS Tg+/dko) and analyzing the effects of the transgene on
survival, fibrosis, inflammation and muscle damage.
Materials and Methods
Mice
All experiments involving animals were performed according to
the National Institutes of Health Guide for the Care and Use of
Laboratory Animals. The protocols were approved by the Animal
Research Committee of the University of California, Los Angeles
(AWA Assurance #A3196-01). Mice were housed in the UCLA
vivarium and examined daily for signs of distress, injury or disease.
Mice who displayed signs of sickness or distress such as
dehydration, inability to locomote or skin ulceration were
euthanized by isoflurane inhalation.
Mdx female mice heterozygous for utrophin (mdx;utr+/2; gift
from Dr. Mark Grady (Washington University, St. Louis) and Dr.
Joshua Sanes (Harvard University, Cambridge)) were bred with
muscle-specific nNOS transgenic males [17] on an mdx
background (nNOS Tg+/mdx) to generate F1 offspring that are
all dystrophin-deficient with some heterozygous for utrophin and
nNOS transgene expression (nNOS Tg+/2;mdx;utr+/2). The F1
male nNOS Tg+/mdx;utr+/2 mice were identified by PCR using
genomic tail DNA as previously described [17,36,37] and back-
crossed with mdx;utr+/2 females. The resulting F2 litters were
screened to identify the dystrophin and utrophin knock-outs (dko)
with (nNOS Tg+/dko) and without (nNOS Tg-/dko) nNOS
transgenic expression that were subsequently used for experimen-
tation. The nNOS transgenic line used in these studies shows
transgene expression in skeletal and cardiac muscle [18].
nNOS expression
Whole extracts of tibialis anterior muscle were loaded to 10%
acrylamide gels (30 mg protein per lane as determined by the
method of Minamide [38]) and electrophoresed according to
Laemmli [39]. Following electrophoretic transfer to nitrocellulose
membrane while immersed in transfer buffer (39 mM glycine,
48 mM Tris, 0.037% sodium dodecyl sulfate, 20% methanol) [40],
loading uniformity and transfer efficiency were assessed by staining
with 0.1% Ponceau S (Sigma, St. Louis, MO). Subsequently, the
membranes were incubated in blocking buffer (0.5% Tween-20,
0.2% gelatin and 3% dry milk) for one hour at room temperature
to inhibit non-specific binding. The membranes were probed with
mouse anti-nNOS (Transduction Labs, Franklin Lakes, NJ) for
2 hours at room temperature followed by horseradish peroxidase
(HRP)-conjugated anti-mouse IgG (Amersham, Piscataway, NJ)
for one hour. Membranes were washed with 0.1% Tween in PBS
between incubations. nNOS bands were visualized using
enhanced chemiluminescence and expression was quantified
densitometrically using imaging software (Alpha Innotech, San
Leandro, CA).
nNOS localization
Mice were euthanized at 51–53 days of age via isoflurane
inhalation and tissues for histological analysis were collected
immediately and frozen in isopentane at 280uC until being cut
into 10 mm cross-sections. Sections were air-dried and fixed in cold
acetone, followed by incubation with 2% gelatin and 3% bovine
serum albumin in phosphate buffered saline (PBS) to prevent non-
specific binding of antibodies. Sections were then incubated with
rabbit anti-human nNOS (Serotec, Oxford, UK) overnight at 4uC,
for 1 hour at room temperature with a biotinylated anti-rabbit
secondary antibody (Vector Laboratories, Burlingame, CA) and
then for 30 minutes at room temperature with Texas Red-labeled
avidin D (Vector Laboratories). Sections were washed with PBS
between incubations.
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Nitric oxide was detected in situ using 4,5-diaminofluorescein
diacetate (DAF-2 DA, EMD Chemicals, San Diego, CA)
according to Heydemann et al. [41]. Ten micron-thick, frozen,
quadriceps sections were incubated with 100 mM DAF-2 DA in
DMEM containing 10% fetal bovine serum and 500 mML -
arginine (EMD) for 30 minutes at 37uC. Sections were then
washed in PBS twice, for 5 minutes and mounted. Signal
specificity was confirmed by treating negative control slides with
1 mM N-nitro-L-arginine methyl ester hydrochloride (Sigma) to
inhibit NOS activity. DAF-2 DA staining was visualized and
quantified under fluorescent optics. A pre-determined and random
pattern containing 5 areas and totaling at least 1000 fibers was
quantified in each section. The intensity of fluorescence in each
fiber was measured via digital imaging (Bioquant, Nashville, TN)
by sampling from an 8 mm diameter circle and was corrected for
background levels by measuring the signal from an area of the
slide with no tissue and subtracting that background value from
the cytosolic fluorescence measurements. Measurements and
images were obtained below saturation levels with exposure kept
constant for all samples.
Quantitative immunohistochemistry
Tissues were collected and stored in isopentane as described
above and quadriceps, solei, hemi-diaphragms and hearts were cut
into 10 mm cross-sections. Sections were then air-dried and fixed
in cold acetone, and endogenous peroxidase activity was quenched
with 0.03% hydrogen peroxide. Sections were incubated with 2%
gelatin and 3% bovine serum albumin in PBS to prevent non-
specific binding of antibodies. Primary antibodies were applied for
2 hours at room temperature in a humidified chamber followed by
host-appropriate biotinylated secondary antibodies (Vector Labo-
ratories) for 30 minutes at room temperature and finally, HRP-
avidin D for 30 minutes. Sections were washed with PBS between
antibody incubations. Labeled cells were visualized using 3-amino-
9-ethyl carbazole (AEC, red) (Vector Laboratories) as substrate.
Immunofluorescent labeling was performed using FITC- or Texas
Red-conjugated secondary antibodies (Vector Laboratories) for 30
minutes at room temperature following incubation with the
primary antibody as described above. ProLong Gold mounting
medium (Invitrogen, Carlsbad, CA) containing DAPI was used to
conterstain nuclei. Antibodies used for inflammatory cell-staining
were anti-mouse CD4 from supernatants of hybridoma cultures
(hybridomas obtained from American Type Culture Collection,
Bethesda, MD), rat monoclonal anti-mouse CD8 (Southern
Biotech, Birmingham, AL), anti-mouse CD68 (Serotec, Raleigh,
NC), polyclonal rabbit anti-mouse eosinophil granule major basic
protein (gift from Dr. J.J. Lee, Mayo Clinic Scottsdale, AZ) [42]
and anti-mouse CD163 (Santa Cruz, Santa Cruz, CA). Although
CD68 is reported to be expressed by all macrophages in humans
and in circulating populations in rodents, empirical findings show
that CD68 expression in injured rodent muscle is selective for a
macrophage subpopulation that invades injured tissue rapidly, is
phagocytic and cytotoxic, reflecting M1 activation [43,44,45].
CD163 was selected as an M2 macrophage marker because
CD163+ macrophages are activated by Th2 cytokines such as IL-
10 and IL-4, they express transcripts associated with M2 activation
and they invade injured muscle subsequent to invasion by CD68+
M1 macrophages [44,46,47].
The concentrations of inflammatory cells were measured by
histomorphometry by an investigator who was blinded to the
genotype of each sample. The total number of positively stained
cells in an entire cross-section from each sample was counted and
the area of the cross-section was measured using an eyepiece
containing a calibrated 10610 grid so that the concentration of
cells per volume of the tissue section could be calculated using the
known thickness (10 mm) of the section, as previously described
[48].
Fibrosis assay
Connective tissue content of quadriceps, solei, hearts and
diaphragms was quantified by measuring the amount of
hydroxyproline in the tissues according to the technique of
Kivirikko et al. [49] that we have used previously [18].
Immunofluorescent labeling for collagen type 1 was performed
on 10 mm-thick tissue sections. Sections were fixed and non-
specific binding of antibodies was prevented as described above.
Sections were incubated with rabbit anti-rat collagen type 1
(Chemicon, Temecula, CA) for three hours at room temperature
followed by a Texas Red-conjugated anti-rabbit secondary
antibody (Vector) for 30 minutes at room temperature. Sections
were washed with PBS between antibody incubations.
Fiber damage assays
Lesions in soleus muscle fibers were assayed two ways by
measuring the presence of the fluorescent, extracellular tracer day,
procion orange in the cytosol of the muscle fibers. Procion orange
is a vital dye that is not actively transported across cell membranes,
instead entering through membrane lesions. Thus, its presence in
the cytosol indicates an injured fiber in which there is unregulated
transit of large molecules across the membrane. Freshly-dissected
soleus muscles were mounted at rest length and incubated in 0.5%
procion orange in Kreb’s Ringer solution for 1 hour at room
temperature and then washed with Kreb’s Ringer before being
frozen in isopentane and subsequently cut into 10 mm-thick cross-
sections. The sections were viewed microscopically using fluores-
cent optics and the bright fibers indicating the presence of
membrane lesions were counted and expressed as a percentage of
the total number of fibers in a given section. We also measured the
fluorescence intensity of each fiber in a cross-section using a digital
imaging system (Bioquant) as described above.
Statistics
Statistical differences between experimental groups were
determined using the two-tailed Mann-Whitney test. Survival
data are displayed as Kaplan-Meier plots and statistical signifi-
cance between the curves was tested using the Log Rank test.
Significant differences in survival at a specific age or with regard to
mean life-span were tested using the x
2 test or the Mann-Whitney
U test, respectively. P-values were set at 0.05.
Results
nNOS transgene expression increases survival in dko
mice
Life-span data were collected from nNOS TG+/dko and nNOS
TG-/dko mice for which transgene expression or absence was
confirmed by western blots (Figure 1A.). Densitometric analysis of
western blots showed that the nNOS TG+/dko mice exhibit a
200% increase in nNOS expression as compared to nNOS TG-/
dko mice (n=5 per group). Likewise, production of NO was
increased by 42% in muscle from dko mice expressing the nNOS
transgene (Figure 1B–E). The Kaplan-Meier survival curve of the
nNOS TG+/dko mice was significantly different from the nNOS
TG-/dko mice showing that the nNOS transgene improved
survival (p=0.048) (Figure 2) and produced a significant, 12%
increase in mean life-span (67 days, sem=2.4 vs. 75 days, sem=2.9;
p=0.041). The nNOS transgene was also associated with a delay
Cytosolic nNOS Increases Lifespan in Mdx Dystrophy
PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e25071in the onset of mortality with the first nNOS TG-/dko mouse
dying at 35 days of age while the first nNOS TG+/dko mouse did
not die until 54 days of age. Based on these findings, we performed
all subsequent experimentation on nNOS TG+/dko and nNOS
TG-/dko mice at 51–53 days of age because 100% of the nNOS
TG+/dko population was alive and survival between the two
groups differed significantly at this time point (p=0.044)
indicating that the nNOS transgene affected onset of the fatal
pathology.
Expression of a nNOS transgene does not affect muscle
fiber lysis in dko mice
Assays of muscle fiber damage indicated by the unregulated
influx of extracellular marker dye into the cytosol of muscle fibers
showed that nNOS transgene expression had no significant effect
on muscle fiber injury in dko mice (Figure 3). Both nNOS TG+/
dko and nNOS TG-/dko mice showed a biphasic distribution of
fiber injury that resembled the distribution of injury that was
previously observed in 12-week-old mdx muscle [47], indicating
that the biphasic distribution does not require utrophin mutation.
The lack of effect of nNOS transgene expression on the magnitude
of muscle fiber injury is in contrast to findings in mdx mice in which
expression of the nNOS transgene resulted in a 70% decrease in
muscle fiber lysis due to decreased macrophage infiltration [17].
nNOS TG+/dko mice show a specific reduction in
pro-fibrotic, M2c macrophages that is associated with a
significant decrease in muscle fibrosis
Because nNOS transgene expression did not reduce muscle
fiber injury in dko muscle although previous work showed that
expression of the transgene in mdx muscle reduced fiber damage
and the numbers of cytolytic macrophages in muscle, we tested
whether the nNOS transgene affected inflammation in dko
muscles. We found that the concentration of M1 macrophages,
Figure 1. nNOS protein and nitric oxide are increased in dko mice expressing a nNOS transgene. A. Overexpression of the nNOS
transgene was confirmed by western blots for all mice assayed in the investigation. Upper panel shows a blot for nNOS in a representative nNOS TG+/
dko muscle extract (Tg+) and a representative nNOS TG-/dko extract (TG-). Lower panel shows the same blot stained with Ponceau red prior to
antibody labeling to confirm uniform loading of samples. B. Percent cytosolic nitric oxide (NO) in wild-type (white bar), nNOS TG-/dko (black bar) and
nNOS TG+/dko (grey bar) muscle. n=5 mice per group. Error bars represent standard error of the mean. * = significant difference as compared to
wild-type. # = significant difference as compared to nNOS TG-/dko. p,0.05. C. Wild-type muscle showing NO present in the cytosol and highly
concentrated at the sarcolemma. Bar=50 mm. D. nNOS TG-/dko muscle exhibits low levels of NO in muscle fibers, but strong NO production by
infiltrating mononuclear cells (arrow). E. Increased levels of NO are evident in the cytosol of muscle fibers from nNOS TG+/dko mice.
doi:10.1371/journal.pone.0025071.g001
Figure 2. nNOS transgene expression significantly increases
survival in dko mice. Survival of nNOS TG-/dko mice (black line,
n=24) and nNOS TG+/dko mice (red line, n=18) is plotted as Kaplan-
Meier curves. The survival curve of nNOS TG+/dko mice is significantly
different from nNOS TG-/dko mice at p,0.05.
doi:10.1371/journal.pone.0025071.g002
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nNOS transgene (control vs. nNOS TG+/dko, soleus: 41,859
cells/mm
3, SEM=9428 vs. 48,191, SEM=7272, quads: 12,685
cells/mm
3, SEM=1567 vs. 14,017, SEM=1651), heart (11,228
cells/mm
3, SEM=1739 vs. 10,713 cells/mm
3, SEM =1364) and
diaphragm: (22,324 cells/mm
3, SEM=4696 vs. 21,938 cells/
mm
3, SEM=3120) (Figures 4 and 5). However, the concentration
of CD163+, M2 macrophages was significantly reduced in nNOS
TG+/dko muscles (soleus: 12,288 cells/mm
3, SEM=2362 vs.
5762, SEM=418; quads: 4389 cells/mm
3, SEM=577 vs. 1860,
SEM=381; heart: 10,918 cells/mm
3, SEM=655 vs. 5645 cells/
mm
3, SEM =612; diaphragm: 7808 cells/mm
3, SEM=431 vs.
3819 cells/mm
3, SEM=623) (Figures 4 and 5). We did not
observe any change in the concentrations of neutrophils, CD4+ or
CD8+ T-cells associated with nNOS transgene expression,
although we noted a significant increase in eosinophils in the
hindlimb muscles of nNOS TG+/dko mice as compared to
controls (soleus: 4161 cells/mm
3, SEM=515 vs. 6592 cells/mm
3,
SEM=521; quadriceps: 4052 cells/mm
3, SEM=500 vs. 6175
cells/mm
3, SEM=601) (Figure 6).
Since M2 macrophages express arginase and promote fibrosis,
we assayed whether the reduction of CD163+ macrophages
affected muscle fibrosis in dko mice expressing the nNOS
transgene. The nNOS TG+/dko mice experienced significantly
less fibrosis in soleus, quadriceps, heart and diaphragm muscle
suggesting that the nNOS transgene reduced fibrosis by modulat-
ing the M2 macrophage numbers (Figures 7 and 8). The
relationship between nNOS and dystrophic fibrosis is further
illustrated by linear regression analysis showing that nNOS
expression is inversely correlated with fibrosis in dko mice
(Figure 9). These data suggest that the decrease in fibrosis could
contribute to the increased survival rate and lifespan of the nNOS
TG+/dko mice.
nNOS protein is cytosolic in nNOS transgenic, dko mice
Most nNOS protein in skeletal muscle is normally localized at
the cell membrane as part of the dystrophin protein complex via
interactions with syntrophin [50]. However, nNOS is dramatically
down-regulated in both the membrane and cytosolic compart-
ments in dystrophin-deficient muscle [12,13]. Recent publications
propose that restoration to the sarcolemma is necessary for
functional nNOS signaling in dystrophic muscle [51,52]. On the
contrary, we did not detect nNOS protein at the sarcolemma in
the nNOS TG+/dko muscle, but detected nNOS only in the
cytosol with increased nNOS expression in nNOS TG+/dko
hindlimb, cardiac and respiratory muscles (Figure 10). From this
observation we conclude that sarcolemmal localization is not
required for nNOS to be beneficial in reducing the dystrophic
pathology and most importantly, extending survival in nNOS
TG+/dko mice.
Body mass and muscle mass of dko mice are not affected
by nNOS transgene expression
Reflective of severe skeletal muscle disease and atrophy, dko
mice are smaller than wild-type [53] and mdx mice [34,35] and
experience continuing weight-loss prior to death [35]. Attenuation
of body mass loss has been observed in dko mice with prolonged
survival due to expression of dystrophin complex proteins,
including nNOS [54], which indicates a decrease in muscle
atrophy that could be a factor in extending life-span. We
determined whether similar benefits occurred in the nNOS
TG+/dko mice since nNOS expression was increased and the
mice lived longer. However, body mass and muscle mass of the
nNOS TG+/dko mice did not differ from non-transgenic controls
(Figure 11, Table 1) showing that amelioration of muscle atrophy
does not contribute to the nNOS transgene-associated increase in
life-span.
Discussion
Our findings show that deficits in nNOS expression and NO
production contribute to a shortened life-span in a severe model of
DMD, the dystrophin/utrophin double knockout mouse. While
deficiencies in nNOS are secondary to the disease etiology, lack of
nNOS protein and the signaling effects of its metabolic product,
NO, can promote multiple components of the pathophysiology
including inflammation [17], muscle fiber lysis [17], defects in
neuromuscular junction structure [55], fibrosis [18], cardiac
functional deficits [18,20], and misregulation of intramuscular
blood flow [56,57]. By expressing nNOS from a muscle-specific
transgene, we were able to significantly delay the onset of the fatal
Figure 3. nNOS transgene expression does not reduce muscle
fiber damage in dko mice. A. The percentage of damaged fibers in
soleus muscles of nNOS TG-/dko mice (black bar) and nNOS TG+/dko
mice (grey bar) does not differ. n=5 mice per group. B. The aggregate
distribution of intracellular fluorescence in all soleus fibers from each
group. A rightward shift on the abscissa would indicate an increase in
the number of fibers with lesions. The black and white, striped peaks
represent fibers of nNOS TG-/dko mice, the red peaks represent fibers
from nNOS TG+/dko mice and the striped, red areas indicate overlap
between the groups. n=5 mice per group.
doi:10.1371/journal.pone.0025071.g003
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of nNOS TG+/dko mice was associated with a significant
reduction in pro-fibrotic, M2c macrophages and connective tissue
content of skeletal muscle and cardiac tissue suggesting that the
nNOS transgene enhanced longevity by attenuating fibrosis.
Surprisingly, expression of the nNOS transgene had different
effects in dko and mdx mice. Our previous work showed that
nNOS transgene expression in muscle of mdx mice significantly
reduced muscle fiber damage [17]. This decrease in muscle lysis
was attributed to a nNOS transgene-induced reduction in
cytotoxic muscle macrophages. Since total macrophage concen-
trations in nNOS TG+/dko were reduced by magnitudes
comparable to those in nNOS TG+/mdx mice, we anticipated a
similar effect on fiber lysis. However, muscle fiber damage was not
attenuated in the nNOS TG+/dko mice indicating that a
reduction of muscle necrosis did not contribute to the increase
in dko lifespan. Instead, this suggested a functional distinction
between the macrophage populations present in mdx and dko
muscles. Accordingly, we confirmed that the nNOS transgene did
not affect the concentration of cytolytic, CD68+ M1 macrophages
in dko mice but had a significant and specific effect in reducing the
concentration of pro-fibrotic, CD163+ M2c macrophages. The
different effects of the nNOS transgene are likely due to differences
in the disease processes between dko and mdx mice at the times
sampled. The 4-week time point in mdx mice is dominated by pro-
inflammatory signals and represents the acute peak of pathology
with significant muscle necrosis, whereas the time point we
sampled in dko mice is largely pro-fibrotic and indicative of the
disease’s end-stage. The difference in magnitude of nNOS
overexpression between the mdx and dko strains could also
contribute to the variable effects on the pathologies. The dko mice
Figure 4. nNOS reduces pro-fibrotic, CD163+ macrophage concentrations in dko skeletal and cardiac muscle. The concentration of
CD68+ and CD163+ macrophages was quantified in soleus (A), quadriceps (B), heart (C) and diaphragm (D) muscles of nNOS TG-/dko mice (black
bars) and nNOS TG+/dko mice (grey bars). * = significant difference in cell concentration as compared to non-transgenic mice at p,0.05. n=5 mice
per group.
doi:10.1371/journal.pone.0025071.g004
Figure 5. CD163+ macrophage infiltration is decreased in
nNOS TG+/dko muscle. CD68+ (green) and CD163+ (red) macro-
phages were immunolabeled in quadriceps sections. Nuclei were
counterstained with DAPI (blue). There is no difference in the number of
CD68+ macrophages between nNOS TG+/dko (A) and nNOS TG-/dko (B)
muscles. However, there are fewer CD163+ macrophages in nNOS TG+/
dko muscle (C) as compared to nNOS TG-/dko muscle (D). Bar=50 mm.
doi:10.1371/journal.pone.0025071.g005
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counts from soleus muscle. PMN = neutrophils, EOS = eosinophils, CD4
+ = CD4
+ cells, CD8
+ = CD8
+ cells. Black bars = nNOS TG-/dko, grey bars =
nNOS TG+/dko. B. Inflammatory cell counts from quadriceps muscles. C. Inflammatory cell counts from cardiac muscle. D. Inflammatory cell counts
from diaphragm muscle. n=5 mice per group. * = significant difference as compared to same muscle from non-transgenic mice at p,0.05. Some
error bars are too small to visualize.
doi:10.1371/journal.pone.0025071.g006
Figure 7. Skeletal and cardiac muscle fibrosis is significantly reduced in dko mice expressing a nNOS transgene. Connective tissue
content of soleus, quadriceps (Quad.), heart and diaphragm (Diaph.) muscles from nNOS TG-/dko mice (black bars) and nNOS TG+/dko mice (grey
bars) was quantified by measuring hydroxyproline levels. * indicates significant difference from nNOS TG-/dko at p,0.05. n=5 mice per group.
doi:10.1371/journal.pone.0025071.g007
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nNOS expression whereas mdx mice expressing the same
transgene demonstrate a 500% increase in nNOS expression
(data not shown). While significant benefits were observed in the
nNOS TG+/dko mice, nNOS expression was only 17% of that in
wild-type mice. Also unexpected, nNOS TG+/dko hindlimb
muscles showed higher eosinophil concentrations than nNOS
TG-/dko hindlimb muscle, despite previous findings that
eosinophils can promote fibrosis in mdx muscle [58]. However,
increased NO generated by the transgenic nNOS protein may
have stimulated eosinophil migration, as previously demonstrated
in vitro using human eosinophils [59].
Increased fibrosis that is associated with nNOS deficiency
relates closely to the early death of dko mice. Pathological
deposition of connective tissue is an underlying factor in the two
primary causes of death in DMD: respiratory and cardiac
dysfunction [60–63]. The dko mouse similarly experiences these
aspects of the dystrophic pathology validating its use as a model for
the disease. Previous studies showed that dko mice exhibit
increased cardiac fibrosis, stiffness and conduction defects that
replicate those observed in DMD patients [20,35,64,65]. Likewise,
dko mice develop severe fibrosis of the diaphragm [35] causing
respiratory impairment that is characteristic of the dystrophic
pathology [66]. Since both clinical and experimental findings
Figure 8. Fibrotic lesions are reduced in skeletal muscle and heart of nNOS TG+/dko mice. Immunofluorescent labeling for collagen type
1 in soleus, quadriceps, heart and diaphragm muscles revealed less fibrosis in dko mice expressing the nNOS transgene. Top row = nNOS TG-/dko
tissues. Bottom row = nNOS TG+/dko tissues. Bar=50 mm.
doi:10.1371/journal.pone.0025071.g008
Figure 9. Fibrosis is inversely correlated with nNOS expression in dko muscle. Linear regression was used to quantify the relationship
between nNOS expression (measured densitometrically following western blotting) and hydroxyproline content in quadriceps muscles from nNOS
TG+/dko and nNOS TG-/dko mice. n=5 mice per group.
doi:10.1371/journal.pone.0025071.g009
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dysfunction and cardiomyopathy that are the leading causes of
death in dystrophin-deficient dystrophy, the extended lifespan of
nNOS Tg+/dko mice may reflect the decreased fibrosis that
occurred in respiratory and cardiac muscles. We are not able to
determine whether the reductions of fibrosis in cardiac, diaphragm
or limb muscles all contribute to increasing dko survival, although
it has been shown that specific restoration of diaphragm or skeletal
muscle function can rescue cardiac function in dko mice [67,68].
Sarcolemmal localization of nNOS was not required to increase
survival of nNOS TG+/dko mice or to decrease cardiac or skeletal
muscle fibrosis in the disease. Nevertheless, several previous
reports have suggested that nNOS localization to the cell
membrane may be a significant feature in reversing other aspects
of the dystrophic pathology. For example, mice that are null
mutants for a-syntrophin showed a large reduction in sarcolemma-
associated nNOS that is accompanied by defects in autonomic
regulation of vasoconstriction [69]. However, total nNOS is also
reduced in the muscles of a-syntrophin null mice, so whether the
defects were attributable to a loss of membrane-associated nNOS
per se or caused by a loss of total NO production by muscle remains
unknown. Similarly, excised muscles from nNOS null mice, that
lack both membrane-associated and cytosolic nNOS, showed
increased fatigability and reduced force production, which was
consistent with the possibility that loss of membrane-associated
nNOS caused the defects [52]. However, whether those functional
deficits could be reversed by restoring cytosolic nNOS has not
been tested. In other studies, slower recovery from exercise and
loss of normal regulation of vasodilation were reported in mutant
mice that express e-sarcoglycan instead ofa-sarcoglycan at the
muscle membrane [51]. These mice experience loss of nNOS from
the sarcolemma and small reductions in total nNOS [51] which
could indicate that the specific loss of membrane-localized nNOS
rather than reductions in total nNOS were most important in the
functional deficits that were reported. However, when the mice
were treated with phosphodiesterase 5A (PDE5A) inhibitor, post-
exercise fatigue was reduced [51]. Similarly, PDE5A treatments of
mdx mice reduced post-exercise fatigue and improved vasodilation
Figure 10. nNOS expression is localized to the cytosol in nNOS
TG+/dko mice. Immunofluorescent labeling for nNOS in hindlimb,
cardiac and respiratory muscles. A. nNOS is present at the sarcolemma
in C57 quadriceps. B. A single, revertant fiber (arrow) in nNOS TG+/dko
quadriceps shows sarcolemmal localization of nNOS as opposed to the
cytosolic staining throughout the section. C, E, G. nNOS TG-/dko
quadriceps (C), heart (E) and diaphragm (G) muscles show no
sarcolemmal nNOS expression and barely detectable to low levels of
cytosolic nNOS expression. D, F, H. Increased levels of cytosolic nNOS
expression are detectable in quadriceps (D), heart (F) and diaphragm (H)
muscles of nNOS TG+/dko mice. Bar = 50 mm.
doi:10.1371/journal.pone.0025071.g010
Figure 11. nNOS transgene expression does not prevent
atrophy in dko mice. Body masses of nNOS TG-/dko (open squares,
n=9) and nNOS TG+/dko (filled triangles, n=8) mice are plotted as a
function of time and show no difference between groups. There was no
significant difference between the body masses of males and females
within each group, so data from both genders were combined.
doi:10.1371/journal.pone.0025071.g011
Table 1. Body and muscle masses of nNOS TG- and nNOS
TG+/dko mice.
Body mass Quad. TA Soleus Gastroc. Heart
nNOS TG-/dko 18.6 (0.89) 124.5
(12)
34.9
(1.8)
8.4 (0.67) 87.6 (8.1) 74.0 (7.2)
nNOS TG+/dko 16.2 (0.76) 112.1
(7.5)
36.0
(1.9)
9.1 (0.78) 90.4 (6.2) 86.0 (4.0)
Masses are in grams (standard error of the mean) and were measured at 51–53
days of age. nNOS TG-/dko =9 mice. nNOS TG+/dko =8 mice. Quad. =
quadriceps, TA = tibialis anterior, Gastroc. = gastrocnemius. There were no
significant differences between male and female body or muscle masses in a
group, so values were combined.
doi:10.1371/journal.pone.0025071.t001
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recovery following exercise because PDE5A inhibits the degrada-
tion of cGMP which is a signaling molecule generated downstream
of NOS activation; thus, PDE5A treatments can compensate for
deficiencies in NO production. However, since neither mouse
strain expressed membrane-associated nNOS, the NO-mediated
improvement in function in PDE5A-treated mice occurred
independently from nNOS localization to the sarcolemma,
indicating that increased activation of cytosolic nNOS reduced
the functional defects. Furthermore, increased expression of
cytosolic nNOS in mdx muscle produced great reductions in
fatigability during treadmill running [70], showing that increasing
total NO production in muscle is sufficient to reduce fatigue,
independent of nNOS localization within the cell.
The extent of pathology in dystrophic mice expressing modified
dystrophin proteins is also not correlated with sarcolemmal
localization of nNOS. Previous studies have shown remarkable
success in preventing or reducing disease in dystrophin-deficient
mice expressing mini- and micro-dystrophin constructs that induce
reorganization of the dystrophin glycoprotein complex
[53,54,71,72]. Dystrophin-deficient mice expressing the most
effective micro-dystrophin construct, DR4-R23, had morpholog-
ically normal muscles that were free of fibrosis, necrosis and
inflammation and demonstrated normal resistance to contraction-
induced injury [71,72]. Significant levels of nNOS were found in
cytosolic fractions of muscles from DR4-R23 mice, although
nNOS in DR4-R23 mdx mice was primarily cytosolic and was
only barely detectable in microsomal preparations and minimally
expressed at the sarcolemma in tissue sections [72]. Expression of a
similar dystrophin construct, DR4-R23/DC, in utrophin/dystro-
phin double-mutant mice yielded benefits comparable to those
observed with DR4-R23 but also failed to restore nNOS to the
sarcolemma [53]. Furthermore, the DH2-R19, mini-dystrophin
construct also generated mdx mice with normal muscle morphol-
ogy and specific force levels [71] while little nNOS was localized to
the sarcolemma [72]. In contrast, transgenic mdx mice with skeletal
muscle expression of Dp260, the retinal isoform of dystrophin,
showed significant nNOS expression in muscle membrane
fractions yet still exhibited fibrosis, inflammation, degeneration
and reduced force production although the pathology was less
severe than in mdx mice not expressing Dp260 [73]. Interestingly,
lack of nNOS at the sarcolemma does not limit voluntary activity
in mdx mice. The DR4-R23 and DH2-R19 mdx mice were able to
run significantly further than wild-type mdx mice and as far or
further than C57Bl/10, control mice [71]. The dystrophic models
described above show that disease phenotype is not correlated with
the extent of sarcolemmal nNOS localization, but can be
influenced by the characteristics of the dystrophin proteins
expressed and the mechanical integrity of the transmembrane
complex formed.
Although published findings do not permit conclusions to be
made concerning whether nNOS-mediated rescue of dystrophin-
deficient muscle is more efficient if nNOS is membrane associated,
numerous findings have shown broad, significant, beneficial effects
of increased expression of cytosolic nNOS for reducing the
pathology of muscular dystrophy. For example, expression of a
nNOS transgene in mdx muscles that produces an elevation of
cytosolic nNOS reduces muscle fiber damage [17], reduces muscle
inflammation [17], decreases skeletal muscle and cardiac fibrosis
[10,18], reduces cardiac dysfunction [18], reduces kyphoscoliosis
[10], improves neurogenesis [74], provides positive allosteric
regulation of phosphofructokinase [70], raises systemic levels of
circulating NO [74] and reduces muscle fatigability [70].
Furthermore, elevated NO production caused by increased
expression of cytosolic nNOS plays significant regulatory roles in
non-dystrophic muscles. For example, increased NO production
by cytosolic nNOS modulates the redox balance in muscle and the
expression of superoxide dismutase and peroxiredoxin [75] and
reduces muscle inflammation and injury during modified muscle
use [76]. Notably, all of these beneficial effects were mediated by a
transgene that expressed a protein that did not include the m-
peptide that is present in native nNOS in skeletal muscle, showing
that nNOS rescue of muscle function does not require expression
of the nNOSm isoform. However, it is feasible but untested that the
rescue by increased expression of the nNOSm isoform may be
more, or less, efficient than rescue by the nNOS isoform lacking
the m-peptide.
The current study shows that muscle-specific expression of a
nNOS transgene in dko mice has significant benefits that delay the
onset of fatal pathology and extend life-span. We determined that
nNOS transgene expression significantly decreased fibrosis in
cardiac, diaphragm and hindlimb muscles by reducing the
concentration of pro-fibrotic macrophages in those tissues. The
abatement of fibrosis is likely the primary factor for extending
lifespan by improving cardiac and diaphragmatic function.
Importantly, the sarcolemmal localization of nNOS was not
required to produce these benefits. These findings show that
increased nNOS expression in the absence of nNOS targeting to
the sarcolemma can significantly ameliorate the pathology and
produce clinically relevant outcomes. This knowledge may be
therapeutically important because we anticipate that pharmaco-
logical or genetic interventions that are directed to increasing total
NO production by muscle can be developed much more rapidly
than interventions that require targeting nNOS specifically to the
cell membrane. We hope that continuing research into the roles of
nNOS and NO in dystrophic disease mechanisms will lead to a
greater understanding of pathological mechanisms that can
ultimately be exploited therapeutically.
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